TACSTD2 and neoplasm: Consistent with earlier findings, univariable survival analyses conducted on our cohort of over 1,000 CRC cases revealed remarkably diminished OS, DSS, and DFS in patients with tumours expressing TROP2 compared with those with TROP2 negative neoplasms.